



	Laboratorios Farmacéuticos Rovi S.A. y sociedades dependientes	Version 1.0
	GENETIC ENGINEERING	Approval Date: 01/08/2024

GENETIC ENGINEERING POLICY

	Laboratorios Farmacéuticos Rovi S.A. y sociedades dependientes	Version 1.0
	GENETIC ENGINEERING	Approval Date: 01/08/2024

ÍNDICE

1.- INTRODUCTION	3
2.- PURPOSE	3
3.- CONTENT	3
4. DOCUMENT VERSIONS.....	4

	Laboratorios Farmacéuticos Rovi S.A. y sociedades dependientes	Version 1.0
	GENETIC ENGINEERING	Approval Date: 01/08/2024

1.- INTRODUCTION

ROVI GROUP has a clear commitment to regulatory compliance, ethical behavior and transparency, a commitment that is reflected in all its policies and decisions.

2.- PURPOSE

The object of this document is to describe the Genetic Engineering Policy of Rovi Group as a basis of our commitment to the transparency of using this emerging technology.

3.- CONTENT


Genetic engineering (also called genetic modification) is a process that uses laboratory-based technologies to alter the DNA makeup of an organism, that means, the artificial manipulation, modification, and/or recombination of DNA or other nucleic acid molecules in order to modify an organism or population of organisms.

Gene therapy seeks to alter genes to correct genetic defects and thus prevent or cure genetic diseases increasing people's quality of life and providing a benefit to society. Genetic engineering aims to modify the genes to enhance the capabilities of the organism beyond what is normal.

ROVI GROUP acknowledge the risk and controversies associated with the use of this type of emergency technologies as well as the ethical problems that carry out.

ROVI Group has a long history of developing new drugs (it has a wide R&D area) and recognizes the high potential of genetic engineering research, but up to date it has not used this kind of genetic technology in its studies.

However, ROVI GROUP is committed to support further research or engage with stakeholders on emerging technologies that meet the highest ethical standards whether is a high benefit to patients and the treatment has not otherwise been achieved.

	Laboratorios Farmacéuticos Rovi S.A. y sociedades dependientes	Version 1.0
	GENETIC ENGINEERING	Approval Date: 01/08/2024

In such case, ROVI GROUP is committed to report the use of this technology and to act in close collaboration with Authorities and ensuring compliance with current regulatory framework.

In this line, ROVI GROUP commits to avoid the most controversial practices related to these technologies being ethically responsible, scientifically worthy, and conducted in accordance with applicable law.

4. DOCUMENT VERSIONS

Version	Approval Date
1.0	01.08.2024